Boston Scientific stock faces recall scrutiny across device lines

Published on 11/13/2026 at 13:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Boston Scientific stock faces fresh scrutiny after several 2026 device recalls. Quality control and regulatory risks now weigh on the broader growth case.

Recall risks challenge the investment case

Multiple Class-II recalls raise potential remediation costs, regulatory scrutiny and product-disruption risks.
WATCHMAN and electrophysiology remain under pressure, increasing the importance of execution across Boston Scientific's portfolio.
Analysts still see growth potential from interventional cardiology, restructuring savings and the planned Penumbra acquisition.

Boston Scientific, US1011371077, Illustration mit AI erstellt.

Boston Scientific faces renewed investor scrutiny after several voluntary Class II device recalls reported in 2026. In an analysis published on Friday, November 13, Simply Wall St cited firmware problems in a Neuromodulation therapy disc and manufacturing defects in Direxion Torqueable Microcatheters distributed across the United States and international markets.

The recalls do not establish a material financial impact, but they add operational risk to a portfolio already facing pressure in electrophysiology and WATCHMAN. Simply Wall St said the quality issues could lead to rework and remediation costs, tighter regulatory oversight and disruption in interventional and neuromodulation product lines.

Quality adds to existing pressure

The analysis places the recall risk alongside weaker trends in pulsed-field ablation and WATCHMAN volumes. Boston Scientific's broader investment case depends on its cardiovascular and MedSurg portfolio offsetting those weaker franchises while the company executes on restructuring savings and acquisitions.

WATCHMAN remains a key swing factor. Simply Wall St said recent trial results for the WATCHMAN FLX Pro device showed noninferiority for aspirin alone or reduced-dose NOAC regimens versus dual antiplatelet therapy at six months, with similar ischemic stroke rates and less bleeding. The findings could support the franchise if left atrial appendage closure volumes stabilize, but they do not remove the execution risks tied to recalls, competition and integration.

Growth depends on execution

The analysis cited an analyst narrative projecting US$23.0 billion of revenue and US$4.0 billion of earnings by 2029, based on annual revenue growth of 2.9%. It also noted that more optimistic estimates reach US$24.4 billion of revenue and US$4.4 billion of earnings by that year. Those forecasts depend on product quality, supply reliability and the successful integration of Penumbra.

Boston Scientific stock traded at 40.09 euros on Lang & Schwarz at 13:17 CET on Friday, November 13, 2026.